Biofrontera ( (BFRI) ) has shared an announcement.
Biofrontera Inc. announced promising results from its Phase 3 study on Ameluz®-PDT for treating superficial basal cell carcinoma (sBCC). The study, conducted in the U.S., showed highly significant outcomes with 65.5% of patients achieving complete clinical and histological clearance compared to just 4.8% with placebo. With over 3 million sBCC cases annually in the U.S., these findings could lead to a new non-invasive treatment option with reduced patient burden and better cosmetic results. The company plans to submit its findings to the FDA by mid-2025.
For an in-depth examination of BFRI stock, go to TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
